'Status quo bias' affecting take up rate for bowel cancer screening

The NHS has to overcome people’s ‘status-quo bias’ if it is to increase the number of screenings for bowel cancer.

Photo: Status quo bias affecting take up rate for bowel cancer screening

The NHS has to overcome people’s ‘status-quo bias’ if it is to increase the number of screenings for bowel cancer.
Warwick Business School’s Professor Nick Chater revealed on BBC Radio Four’s The Human Zoo that people are victims of ‘status quo bias’ - an irrational preference to maintain the current state of affairs.
This bias is very prevalent and has significant practical implications, for example, in bowel cancer screening: the very possibility of a ‘positive’ test threatens people’s psychological status quo, making it difficult for the NHS to persuade people to come forward for screening.
An experiment involving students at Warwick Business School illustrates the ‘status quo bias’. Students entering a lottery to win £5 were given the choice of swapping their named ticket to win £6, but only 50 per cent of them were willing to do it even though they had the chance of winning more money.
Professor Chater said: “That seems economically irrational - it must be better to have a chance of winning £6 than the same chance of winning £5. But if you take account of the fact that regret is very painful to us, then trying to avoid the regret of giving away what turns out to be the winning ticket is not necessarily irrational at all.
“Whenever we make a decision, we are concerned that we will look back and wished we did something else..”
This fear of a negative outcome seems to be a problem in getting older people to go for bowel cancer screening, with just 51 per cent of those eligible in Scotland taking up the screening and it is a similar picture across the UK. Yet early detection sees nine out of 10 people survive bowel cancer.
Professor Chater said: “If I was trying to persuade people to take the test I would want them to think about the physical status quo rather than their mental status quo.
“If you think about the mental status quo, a test is only likely to disturb the, perhaps complacent, mental status quo you have. If you think the physical status quo is being healthy, the test might help you get the treatment you need to stop the cancer ever happening (if pre-cancerous signs are picked up) or may help return you to health (if cancer is present).
The problem of ‘status quo bias’ afflicts many organisations or companies that are trying to implement change.
“It is everywhere.” said Professor Chater. “Whether or not to keep a ringfence on public health spending is topical at the moment. Most of us have very little idea of the absolute amount of money the government is spending on health or whether it is too little or too much. But the sense that we might reduce spending, moving away from the status quo in a negative way, is very concerning to most of us, and hence to most politicians.”
Listeners can take part in the online ‘status quo bias’ experiment by going to www.weblab.wbs.ac.uk.
 

14.03.2013

Read all latest stories

Related articles

Photo

News • Automated adenoma analysis

AI finds more precancerous polyps than traditional colonoscopy

Colonoscopies performed with AI support may yield an increase in the overall rate of detection of adenoma, or cancerous and precancerous polyps, by 27% in average-risk patients, according to new data.

Photo

News • Prevention improvement

Bowel cancer: most cases diagnosed outside of screening programmes

More than 70% of patients with bowel cancer are not diagnosed using screening programmes meaning diagnoses are often made late, when the cancer is at an advanced stage, according to new research.

Photo

News • Oncology early detection tool

Blood test for 50+ types of cancer promising for screening

Final results from a study of a blood test that can detect more than 50 types of cancer have shown that it is accurate enough to be rolled out as a multi-cancer screening test among people at higher…

Related products

Beckman Coulter – Diazyme Human Kappa & Lambda FLC assays

Clinical Chemistry

Beckman Coulter – Diazyme Human Kappa & Lambda FLC assays

Beckman Coulter Diagnostics
Subscribe to Newsletter